This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.
Our invited speaker, Ilaria Iacobucci of St. Jude Children’s Research Hospital, will discuss the benefits of using single-cell analysis to quantify and characterize genome editing experiments.
In particular, she will discuss a study she co-authored that was published in Blood, “Modeling and targeting of erythroleukemia by hematopoietic genome editing,” in which she developed faithful experimental models of acute erythroid leukemia (AEL) in mice by multiplex genome editing of recurrently co-mutated genes.
As part of this work, Dr. Iacobucci and colleagues used single-cell analysis determine mutational co-occurrence and sequence of acquisition of multiple tumor stages, identifying primary and secondary mutations that promote clonal fitness and genesis of the leukemic phenotype.
Dr. Iacobucci’s presentation will be followed by a live audience Q&A that will discuss this work as well as her experience as a pioneering woman in single-cell research.
Dr. Ilaria Iacobucci, PhD, is a Staff Scientist in the Department of Pathology at St. Jude Children’s Research Hospital. Her research focuses on the understanding of mechanisms underlying the pathogenesis of high-risk myeloid and lymphoid leukemia subtypes in both children and adults through the identification of novel genetic alterations with a diagnostic, prognostic, and therapeutic relevance and the development of preclinical in-vitro and in-vivo models that faithfully recapitulate human leukemia. She has published more than 130 peer-reviewed articles and contributed to the identification of multiple new subtypes of acute lymphoblastic leukemia, such as EPOR-rearranged, DUX4/ERG-deregulated, MEF2D-rearranged and PAX5 P80R mutated. She has defined the genomic landscape of acute erythroid leukemia and identified multiple subgroups with distinct genomic features and transcriptional profiles and generated a number of new engineered mouse models of lymphoid, erythroid and myeloid leukemia that faithfully recapitulate the genetic alterations observed in human diseases.